Mercury Laboratories Limited (BOM:538964)

Market Cap	907.26M -12.8%
Revenue (ttm)	761.53M +6.0%
Net Income	47.19M +19.6%
EPS	39.31 +19.6%
Shares Out	1.20M
PE Ratio	19.23
Forward PE	n/a
Dividend	3.50 (0.44%)
Ex-Dividend Date	Aug 6, 2025

Volume	20
Average Volume	61
Open	761.00
Previous Close	787.95
Day's Range	743.50 - 761.00
52-Week Range	700.00 - 976.00
Beta	0.44
RSI	46.43
Earnings Date	May 8, 2026

About Mercury Laboratories

Mercury Laboratories Limited engages in manufacturing, selling, exporting, and dealing in various pharmaceutical drugs and medicines for mother and child healthcare in India and internationally. The company offers analgesic, anti-inflammatory, anti-pyretic, anthelmintic, antibiotic, anti-coagulant, anti-platelet, bleeding agent, anti-fungal, anti-hypertensive, anti-malarial, cardiovascular system, central nervous system, eye, gastro-intestinal system, hypoglycemic/anti-diabetic, multivitamin, protein supplement, respiratory system, anti-allergi...

• Industry: Pharmaceutical Preparations
• Founded: 1962
• Employees: 503
• Stock Exchange: Bombay Stock Exchange
• Ticker Symbol: 538964

Financial Performance

In fiscal year 2025, Mercury Laboratories's revenue was 751.01 million, a decrease of -0.61% compared to the previous year's 755.59 million. Earnings were 31.45 million, a decrease of -44.38%.